Pediatric Clinical Trials

Pediatric Bone Marrow Transplant

If you would like to inquire about all open trials, please contact 919.684.3401.

4 trials identified.

BMT CTM Protocol 1101 - A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies
Phase: Phase III
Sponsor: Foundation (non-profit group) initiated
Principal Investigator: Joanne Kurtzberg
Contact: Dorothy Mazzitelli, RN
Phone: 919.668.1100
Purpose: Hematopoietic cell transplants (HCT)are one treatment option for people with leukemia or lymphoma. Family members,unrelated donors or banked umbilical cordblood units with similar tissue type can be used for HCT. This study will compare the effectiveness of two new types of bone marrow transplants in people with leukemia or lymphoma: one that uses bone marrow donated from family members with only partially matched bone marrow; and, one that uses two partially matched cord blood units.
Reference Number: 00037305
View this trial at ClinicalTrials.gov

Multi-center, open-label randomized study of single or double myeloablative cord blood transplantation with or without infusion of offâ??the-shelf ex vivo expanded cryopreserved cord blood progenitor cells in patients with hematologic malignancies
Phase: Phase II
Sponsor: External Investigator-Sponsored (External Med Ctr)
Principal Investigator: Joanne Kurtzberg
Contact: Jennifer Baker, RN
Phone: 919.668.6536
Purpose: This randomized phase II trial studies how well donor umbilical cord blood transplant with or without ex-vivo expanded cord blood progenitor cells works in treating patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or myelodysplastic syndromes. Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's cells. When the healthy stem cells and ex-vivo expanded cord blood progenitor cells are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. It is not yet known whether giving donor umbilical cord blood transplant plus ex-vivo expanded cord blood progenitor cells is more effective than giving a donor umbilical cord blood transplant alone.
Reference Number: 00041937
View this trial at ClinicalTrials.gov

A Compassionate Release Protocol: Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Allogeneic Transplantation using a Related Haplo-Identical Donor and Unrelated, Umbilical Cord Blood Donor(s) for the Treatment of High Risk Malignancies or Non-Malignant Disorders Requiring Allogeneic Transplantation
Phase: N/A
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Joanne Kurtzberg
Contact: Jennifer Baker, RN
Phone: 919.668.6536
Reference Number: 00045700

A multicenter study of apheresis collection of peripheral blood mononuclear cells (PBMC) in patients with CD19 expressing malignancies who could be eligible for a CTL019 clinical research trial
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Timothy Driscoll
Contact: Jennifer Baker, RN
Phone: 919.668.1100
Reference Number: 00057365